IN2015KN00350A - - Google Patents

Download PDF

Info

Publication number
IN2015KN00350A
IN2015KN00350A IN350KON2015A IN2015KN00350A IN 2015KN00350 A IN2015KN00350 A IN 2015KN00350A IN 350KON2015 A IN350KON2015 A IN 350KON2015A IN 2015KN00350 A IN2015KN00350 A IN 2015KN00350A
Authority
IN
India
Prior art keywords
present
cancer
agents
methods
rspo3
Prior art date
Application number
Other languages
English (en)
Inventor
Austin L Gurney
Christopher J Bond
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of IN2015KN00350A publication Critical patent/IN2015KN00350A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN350KON2015 2012-07-13 2013-07-12 IN2015KN00350A (enrdf_load_html_response)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261671421P 2012-07-13 2012-07-13
US201361753184P 2013-01-16 2013-01-16
US201361789156P 2013-03-15 2013-03-15
US201361826747P 2013-05-23 2013-05-23
PCT/US2013/050300 WO2014012007A2 (en) 2012-07-13 2013-07-12 Rspo3 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
IN2015KN00350A true IN2015KN00350A (enrdf_load_html_response) 2015-07-10

Family

ID=49914164

Family Applications (1)

Application Number Title Priority Date Filing Date
IN350KON2015 IN2015KN00350A (enrdf_load_html_response) 2012-07-13 2013-07-12

Country Status (24)

Country Link
US (3) US9181333B2 (enrdf_load_html_response)
EP (1) EP2872175A4 (enrdf_load_html_response)
JP (1) JP6335896B2 (enrdf_load_html_response)
KR (1) KR20150036603A (enrdf_load_html_response)
CN (1) CN104854132A (enrdf_load_html_response)
AU (1) AU2013289990B2 (enrdf_load_html_response)
BR (1) BR112015000776A2 (enrdf_load_html_response)
CA (1) CA2878868A1 (enrdf_load_html_response)
CL (1) CL2015000097A1 (enrdf_load_html_response)
EA (1) EA032038B1 (enrdf_load_html_response)
EC (1) ECSP15005280A (enrdf_load_html_response)
HK (1) HK1208687A1 (enrdf_load_html_response)
IL (1) IL236617A0 (enrdf_load_html_response)
IN (1) IN2015KN00350A (enrdf_load_html_response)
MX (1) MX2015000565A (enrdf_load_html_response)
NI (1) NI201500002A (enrdf_load_html_response)
NZ (1) NZ704269A (enrdf_load_html_response)
PE (1) PE20150360A1 (enrdf_load_html_response)
PH (1) PH12015500084A1 (enrdf_load_html_response)
SG (1) SG11201500233PA (enrdf_load_html_response)
TW (2) TWI636061B (enrdf_load_html_response)
UA (1) UA117659C2 (enrdf_load_html_response)
WO (1) WO2014012007A2 (enrdf_load_html_response)
ZA (1) ZA201500872B (enrdf_load_html_response)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02371B (me) 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
PL2173379T3 (pl) 2007-07-02 2016-02-29 Oncomed Pharm Inc Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012174446A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
EP3401329A1 (en) 2011-07-15 2018-11-14 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
AU2013289990B2 (en) 2012-07-13 2018-06-14 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
CN105744954B (zh) * 2013-10-18 2021-03-05 豪夫迈·罗氏有限公司 抗rspo2和/或抗rspo3抗体及其用途
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
CN106687137A (zh) 2014-09-16 2017-05-17 昂考梅德药品有限公司 纤维化疾病的治疗
MA41123A (fr) * 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
WO2017040660A1 (en) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN106913880B (zh) * 2015-12-24 2021-02-12 上海交通大学 一种含有rspo1的靶向给药系统及其制备与应用
CN105925576B (zh) * 2016-03-24 2018-04-20 嘉兴市第一医院 针对哺乳动物R‑Spondin3基因靶点的小干扰RNA、短发卡RNA及载体和应用
US20170319688A1 (en) * 2016-04-14 2017-11-09 Genentech, Inc. Anti-rspo3 antibodies and methods of use
WO2018035210A1 (en) * 2016-08-17 2018-02-22 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with an rspo antagonist
EP4115904A3 (en) * 2017-12-07 2023-04-12 National Health Research Institutes Anti-rspo3 antibodies
CN110339364B (zh) * 2018-04-02 2021-02-12 上海邦耀生物科技有限公司 Lgr4/rspo阻断剂与抗免疫检查点抑制剂联合用于肿瘤的免疫治疗
CN110467663B (zh) * 2019-06-18 2022-05-10 华南农业大学 Rspo3基因在母猪卵巢颗粒细胞中的应用
KR102554222B1 (ko) * 2023-03-21 2023-07-11 순천향대학교 산학협력단 신규한 항-인간 알스폰딘3 항체 및 이의 용도
CN116769030B (zh) * 2023-08-21 2023-10-20 成都大熊猫繁育研究基地 一种大熊猫松弛素3单克隆抗体及其杂交瘤细胞株和应用

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US20070124581A1 (en) 1992-05-17 2007-05-31 Reena Khare Cell adhesion and extracellular matrix proteins
WO1998049302A1 (en) 1997-04-25 1998-11-05 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
WO1999015660A1 (en) 1997-09-24 1999-04-01 Merck & Co., Inc. G-protein coupled glycoprotein hormone receptor hg38
US20020065394A1 (en) 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
JP2002507406A (ja) 1998-03-26 2002-03-12 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 細胞外ロイシンリッチ反復領域を有する新規な哺乳動物ｇ−タンパク質共役型レセプター
US6485972B1 (en) 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
WO2001088088A2 (en) 2000-05-18 2001-11-22 Hyseq, Inc. Novel nucleic acids and polypeptides
US20030166047A1 (en) 1999-05-06 2003-09-04 Millennium Pharmaceuticals, Inc. Lgr6 nucleic acids and uses thereof
EP1196570A2 (en) 1999-07-26 2002-04-17 Genentech, Inc. Human polypeptides and methods for the use thereof
US6824973B2 (en) 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
WO2001057190A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
AU5301201A (en) 2000-03-31 2001-10-15 Gen Hospital Corp Methods of modulating hair growth
JP2003530124A (ja) 2000-04-05 2003-10-14 麒麟麦酒株式会社 新規幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関する方法および物質
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
EP1290030A2 (en) 2000-05-30 2003-03-12 Bayer Aktiengesellschaft Regulation of human lgr4-like g protein-coupled receptor
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6768004B2 (en) * 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
US20040077048A1 (en) 2002-01-30 2004-04-22 Warren Bridget A. Protein modification and maintenance molecules
US20100292155A1 (en) 2001-03-05 2010-11-18 Arca Biopharma, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US20030032034A1 (en) 2001-03-05 2003-02-13 Tang Y. Tom Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US7411052B2 (en) 2001-03-05 2008-08-12 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US7320880B2 (en) 2001-06-11 2008-01-22 Nuvelo, Inc. Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and DNA coding for the same
DE60233509D1 (de) 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
US20030022217A1 (en) 2001-07-02 2003-01-30 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
EP2228443A1 (en) 2001-08-30 2010-09-15 ARCA biopharma, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
JP2005514917A (ja) 2001-10-03 2005-05-26 インサイト・ゲノミックス・インコーポレイテッド 分泌タンパク質
US20070237770A1 (en) * 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
US20040197778A1 (en) 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
AU2002364537A1 (en) 2001-12-07 2003-06-23 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
AU2002366951A1 (en) 2001-12-10 2003-07-09 Nuvelo,Inc. Novel nucleic acids and polypeptides
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
WO2003091280A1 (en) 2002-04-26 2003-11-06 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same
EP1380644A1 (en) 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004074436A2 (en) 2003-02-19 2004-09-02 Incyte Corporation Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer
US20050003405A1 (en) 2003-04-30 2005-01-06 Hua-Chien Chen Treatment and diagnostics of cancer
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
WO2005110009A2 (en) 2003-07-22 2005-11-24 Immunex Corporation COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d
DE10339820A1 (de) 2003-08-22 2005-03-17 Hinzmann, Bernd, Dr. Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
ATE466106T1 (de) 2003-10-10 2010-05-15 Deutsches Krebsforsch Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen
WO2005040828A2 (en) 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
AU2005208945A1 (en) 2004-01-27 2005-08-11 Kyowa Hakko Kirin Co., Ltd. Gastrointestinal proliferative factor and uses thereof
WO2005074633A2 (en) 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
MX2007002883A (es) 2004-09-13 2007-06-15 Macrogenics Inc Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7439327B2 (en) 2005-01-18 2008-10-21 Nuvelo, Inc. Stem cell factor-like proteins and uses thereof
EP2083088A3 (en) 2005-04-07 2009-10-14 Novartis Vaccines and Diagnostics, Inc. Cancer-related genes
JP2009502737A (ja) 2005-07-26 2009-01-29 キリンファーマ株式会社 Ｒ−スポンジンを含有する抗腫瘍薬
WO2007030290A2 (en) 2005-09-07 2007-03-15 Maine Medical Center Research Cristin/r-spondin ligands active in the wnt signaling pathway and methods, compositions and kits relating thereto
EP1942926A4 (en) 2005-10-07 2010-06-16 Nuvelo Inc STEM CELL FACTOR ARTIFICIAL PROTEIN SCFA1 AND ITS USES
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2007053648A2 (en) 2005-10-31 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
NZ573818A (en) 2006-06-02 2011-09-30 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
AU2007254853B2 (en) 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
WO2007145840A2 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008010101A2 (en) * 2006-07-18 2008-01-24 Sanofi-Aventis Antagonist antibody against epha2 for the treatment of cancer
JP2008044926A (ja) 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
ME02371B (me) 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
WO2008046649A1 (en) 2006-10-20 2008-04-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
WO2008075796A1 (ja) 2006-12-21 2008-06-26 Kyowa Hakko Kirin Co., Ltd. 血球回復促進剤
WO2008088524A2 (en) 2006-12-28 2008-07-24 Nuvelo, Inc. Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
JP2010531137A (ja) 2007-06-12 2010-09-24 ワイス・エルエルシー 抗ｃｄ２０治療用組成物および方法
PL2173379T3 (pl) 2007-07-02 2016-02-29 Oncomed Pharm Inc Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CA2700257A1 (en) 2007-10-02 2009-04-09 Hartmut Land Methods and compositions related to synergistic responses to oncogenic mutations
US8680243B2 (en) 2007-11-14 2014-03-25 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-GPR49 antibody
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
WO2010016766A2 (en) 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
CN103408664B (zh) * 2008-10-31 2015-11-25 东丽株式会社 抗人cxcl1单克隆抗体或其片段
EP2419133A1 (en) 2009-04-15 2012-02-22 Deutsches Krebsforschungszentrum Rspondin-3 inhibition in bone disorders
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US20120165270A1 (en) 2009-04-27 2012-06-28 Yeon Sook Choi Inhibition of hair follicle growth by the wnt inhibitor dkk1
AU2010263058A1 (en) 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
US8318162B2 (en) 2009-07-16 2012-11-27 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
ES2788869T3 (es) 2009-09-03 2020-10-23 Merck Sharp & Dohme Anticuerpos anti-GITR
ES2573643T3 (es) 2009-12-23 2016-06-09 Deutsches Krebsforschungszentrum Receptores de Rspo2 y Rspo3
US8663950B2 (en) 2010-01-11 2014-03-04 Arizona Board Of Regents Production of a monoclonal antibody therapeutic against west nile virus in plants
WO2011100566A2 (en) 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
EP2659005A4 (en) * 2010-12-28 2016-08-24 Caris Mpi Inc MOLECULAR PROFILING OF CANCER
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
MX352599B (es) * 2011-04-28 2017-11-30 Sbi Biotech Co Ltd Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.
EP3401329A1 (en) 2011-07-15 2018-11-14 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2013054307A2 (en) 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
EP2773373B1 (en) 2011-11-01 2018-08-22 Bionomics, Inc. Methods of blocking cancer stem cell growth
KR102148303B1 (ko) 2012-02-11 2020-08-26 제넨테크, 인크. R-스폰딘 전위 및 그의 사용 방법
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
AU2013289990B2 (en) 2012-07-13 2018-06-14 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
JP2016518328A (ja) 2013-03-12 2016-06-23 キュアジェニックス インコーポレイテッド 癌治療のための化合物
WO2014192974A1 (ja) 2013-05-30 2014-12-04 株式会社オーダーメードメディカルリサーチ 抗ｌｇｒ６抗体を含む癌の検出用又は診断用試薬
CN105744954B (zh) 2013-10-18 2021-03-05 豪夫迈·罗氏有限公司 抗rspo2和/或抗rspo3抗体及其用途
US9777052B2 (en) 2014-12-02 2017-10-03 The Board Of Regents Of The University Of Oklahoma R-spondin variants, compositions, and methods of use
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer

Also Published As

Publication number Publication date
PH12015500084A1 (en) 2015-03-02
BR112015000776A2 (pt) 2017-08-15
TW201906861A (zh) 2019-02-16
TWI636061B (zh) 2018-09-21
US20170267776A1 (en) 2017-09-21
HK1208687A1 (en) 2016-03-11
MX2015000565A (es) 2015-04-10
US9181333B2 (en) 2015-11-10
CL2015000097A1 (es) 2015-07-10
SG11201500233PA (en) 2015-04-29
JP6335896B2 (ja) 2018-05-30
NI201500002A (es) 2015-07-16
EP2872175A2 (en) 2015-05-20
EA032038B1 (ru) 2019-03-29
AU2013289990A1 (en) 2015-02-19
IL236617A0 (en) 2015-02-26
US20160108130A1 (en) 2016-04-21
AU2013289990B2 (en) 2018-06-14
EA201590144A1 (ru) 2015-08-31
EP2872175A4 (en) 2016-04-20
ZA201500872B (en) 2016-06-29
PE20150360A1 (es) 2015-03-20
UA117659C2 (uk) 2018-09-10
WO2014012007A3 (en) 2014-04-03
KR20150036603A (ko) 2015-04-07
WO2014012007A2 (en) 2014-01-16
NZ704269A (en) 2016-05-27
WO2014012007A4 (en) 2014-05-30
US9598497B2 (en) 2017-03-21
ECSP15005280A (es) 2016-01-29
JP2015529641A (ja) 2015-10-08
US20140017253A1 (en) 2014-01-16
CN104854132A (zh) 2015-08-19
TW201416378A (zh) 2014-05-01
CA2878868A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
IN2015KN00350A (enrdf_load_html_response)
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
CY1121148T1 (el) Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων
PH12018501264A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX2020003719A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
EA033400B1 (ru) Антитело против cd3 и его применение
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
UA107706C2 (uk) Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань
SG10201908388UA (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
PH12015500297A1 (en) Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
AU2011328009A8 (en) Compounds and methods for treating pain
MY173377A (en) Anti-b7-h3 antibody
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
WO2011063237A3 (en) Jagged-binding agents and uses thereof
EA201491352A1 (ru) Способ лечения рака груди
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.
TH163450A (th) เอเจนต์ยึดเกาะ vegf/dll4 และการใช้ของมัน
UA112522C2 (uk) Спосіб терапії злоякісної пухлини